Publications by authors named "M A Middelkamp-Hup"
Article Synopsis
- - The study evaluates the effectiveness and longevity of treatments (dupilumab, methotrexate, and cyclosporine A) for pediatric patients aged 2-17 with severe atopic dermatitis across five centers in the Netherlands from 2013-2023.
- - Out of 502 treatment episodes analyzed, dupilumab showed the highest drug survival rates over three years (84.1% at one year, 72.3% at two, and 62.0% at three), compared to significantly lower rates for methotrexate and cyclosporine A.
- - The main reason for discontinuing treatment was ineffectiveness, especially noted with cyclosporine A, while factors like treatment
Background: Despite the widespread off-label use of methotrexate (MTX) for the treatment of atopic dermatitis (AD), there is limited high-quality evidence on dosing regimens and existing guidelines do not provide clear recommendations regarding dosing strategies.
Objective: The aim of this study was to achieve international consensus among AD experts to standardize the dosing regimen for MTX treatment in adults and children with AD.
Methods: An electronic Delphi (eDelphi) study was conducted from October 2021 to September 2022.
Article Synopsis
- More severe forms of atopic dermatitis and psoriasis significantly impact quality of life, lead to higher healthcare costs, and are linked to other health issues; addressing these problems early can help lessen the burden.
- The BIOMAP consortium is a large-scale research initiative that compiles clinical and molecular data from various studies to improve the understanding of disease severity and identify reliable biomarkers.
- The consortium emphasizes the importance of using consistent definitions for disease severity and considers various factors when analyzing data to ensure that findings are relevant to both patients and healthcare practitioners.
Background: Evidence on the (long-term) safety of systemic immunomodulating therapies in atopic dermatitis (AD) generated by real-world data is sparse.
Objectives: To describe real-world reported adverse drug reactions (AEs) related to systemic immunomodulating therapy in patients with AD and to compare the incidence rates of AEs with the Summaries of Product Characteristics (SmPCs).
Methods: We conducted an observational prospective multi-centre cohort study, using the TREAT NL registry.